Mounjaro vs. Wegovy: Which Weight Loss Injection Is Best for You?

Across the UK, the landscape of medical weight management has undergone a fundamental shift. Weight loss injections—specifically Mounjaro (tirzepatide) and Wegovy (semaglutide)—have become primary clinical tools for managing chronic weight loss, type 2 diabetes risk, and metabolic health.

While both treatments are once-weekly subcutaneous injections approved by the MHRA, they utilize different biochemical mechanisms to regulate appetite, delay gastric emptying, and improve metabolic control.

Patients seeking personalized weight management advice can complete a digital health consultation via the WellAssist Pharmacy Hub or review our essential care services, including Weight Management Solutions, Situational Anxiety Treatments, and Propranolol Services.

The Science in 60 Seconds

Wegovy (semaglutide) is a single-target GLP-1 receptor agonist that slows digestion and increases satiety, producing an average body weight loss of 15% to 17% in clinical trials. Mounjaro (tirzepatide) is a dual-action GLP-1 and GIP receptor agonist that acts on two hormone pathways to deliver superior metabolic regulation and average weight loss of up to 22.5%.

Mechanism of Action: Single vs. Dual Hormone Pathways

                   ┌─────────────────────────────────────────┐
                   │       Endogenous Metabolic Signals      │
                   └────────────────────┬────────────────────┘
                                        │
             ┌──────────────────────────┴──────────────────────────┐
             ▼ SINGLE RECEPTOR AGONISM                             ▼ DUAL RECEPTOR AGONISM
┌─────────────────────────┐                           ┌─────────────────────────┐
│ Wegovy (Semaglutide)    │                           │ Mounjaro (Tirzepatide)  │
│ Targets GLP-1 Receptor  │                           │ Targets GLP-1 & GIP     │
└────────────┬────────────┘                           └────────────┬────────────┘
             │                                                     │
             ▼                                                     ▼
┌─────────────────────────┐                           ┌─────────────────────────┐
│ Delays Gastric Emptying │                           │ Enhanced Satiety &      │
│ Reduces Appetite Signals│                           │ Improved Lipid Handling │
└────────────┬────────────┘                           └────────────┬────────────┘
             │                                                     │
             ▼                                                     ▼
┌─────────────────────────┐                           ┌─────────────────────────┐
│ Average Weight Loss:    │                           │ Average Weight Loss:    │
│ ~15% - 17% Body Weight  │                           │ Up to ~22.5% Body Weight│
└─────────────────────────┘                           └─────────────────────────┘

1. Wegovy: The GLP-1 Receptor Agonist

Wegovy mimics the naturally occurring Glucagon-Like Peptide-1 (GLP-1) hormone. By binding to GLP-1 receptors in the brain’s hypothalamus and gastrointestinal tract, it signals fullness, reduces food cravings, and slows down stomach emptying.

2. Mounjaro: The Twincretin (GLP-1 + GIP)

Mounjaro is classified as a dual GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 receptor agonist. GIP complements GLP-1 by enhancing insulin secretion, optimizing fat metabolism, and significantly lowering hunger levels compared to single-agent treatments.

Head-to-Head Comparison: Wegovy vs. Mounjaro

Feature	Wegovy (Semaglutide)	Mounjaro (Tirzepatide)	Top Page Link
Active Ingredient	Semaglutide	Tirzepatide	WellAssist Pharmacy Hub
Hormone Target	Single GLP-1 Agonist	Dual GIP & GLP-1 Agonist	Weight Management
Avg. Total Weight Loss	15% – 17%	Up to 22.5%	Weight Management Hub
Dosing Frequency	Once Weekly	Once Weekly	Situational Anxiety
Starting Dose	0.25 mg weekly	2.5 mg weekly	Propranolol Services
Common Side Effects	Nausea, constipation, reflux	Nausea, indigestion, diarrhea	WellAssist Hub

Key Guidelines for UK Patients

1. Titration Protocol: Both medications require gradual 4-week dosage escalations (titration) to allow the gastrointestinal tract to adapt and minimize side effects like nausea or heartburn.
2. Eligibility Criteria: Prescriptions in the UK generally require a Body Mass Index (BMI) of 30 kg/m² or above, or a BMI of 27 kg/m² alongside a weight-related comorbidity (e.g., prediabetes, hypertension, hypercholesterolemia).
3. Lifestyle Integration: Injections are designed to support, not replace, a balanced calorie-controlled diet and regular physical activity to preserve lean muscle tissue.